Corporate
News release
TopTOKYO, JAPAN - Dec. 12, 2016 - Terumo Corporation (TSE: 4543) announced today that it has formulated its 5-year Mid- to Long-term Growth Strategy starting from April, 2017. As a global corporation with Japanese origins, we will achieve profitable and sustainable growth by executing the following strategies in a ten-year perspective.
Mid- to Long-term Growth Strategy
- . Win in selected strategic markets
- Select growing segments and segments where Terumo owns a competitive advantage
- oncentrate on intervention, neurovascular, D&D, and therapeutic apheresis
- . Offer comprehensive value in Japan
- Leverage leading position and pursue growth opportunities
- Accelerate innovation
- Contribute to future of healthcare with significant social impact
- Advance core technologies and gain new technologies
Management Indicators for the Next Five Years
(Plan FX rate: USD=105 JPY, EUR=115 JPY)
| Growth: | Faster revenue growth than market growth |
|---|---|
| High single-digit growth in revenue | |
| Profitability: | Faster profit growth than revenue growth |
| Double-digit growth in profit* | |
| Adjusted EPS** 270 - 300 yen by 2021 | |
| Efficiency: | Maintain ROE 10%+*** |
- *
Adjusted operating income (IFRS)
- **
Adjusted items: Intangible asset derived from acquisition, one time acquisition expense, impairment, gain/loss from sales of stocks and others
- ***
Excluding foreign currency translation adjustment balance related to the assets from acquisition included in net assets
For more information, visit http://www.terumo.com/investor/library/material.html
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.